MedTrace Logo

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

NCT04152941 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2023-09-06

No results posted yet for this study

Summary

This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.

Conditions

  • Relapsed Ovarian Cancers Patients

Interventions

DRUG

Olaparib

Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

  • Thibault de La Motte Rouge, Dr · Centre Eugène Marquis

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-11
Primary Completion
2020-02-11
Completion
2020-02-11

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04152941 on ClinicalTrials.gov